Menu

Trump Picks National Cancer Institute Director

Ned Sharpless currently leads the cancer center at the University of North Carolina, Chapel Hill.

Jun 12, 2017
Kerry Grens

BRIAN STRICKLAND/LINEBERGER COMPREHENSIVE CANCER CENTER Update (October 18): Sharpless was sworn in as NCI director today.

President Donald Trump has selected Ned Sharpless, a physician in charge of the cancer center at the University of North Carolina, Chapel Hill, to lead the National Cancer Institute (NCI). The nomination received praise from the cancer research community.

Margaret Foti, the chief scientific officer of the American Association for Cancer Research, says in a statement she is “absolutely thrilled” by Trump’s choice. “[Sharpless’s] enthusiasm for innovative scientific methods and ideas, as well as his appreciation for the value and importance of basic research to advancing translational discoveries, will allow the NCI to continue leading the way in programs aimed at preventing disease, improving health, and reducing suffering from cancer, while also helping to maintain America’s edge in the life sciences.”

Sharpless’s group studies cellular senescence in aging and cancer. In particular, he researches the role of the tumor suppressor p16INK4a in melanoma.

Since Harold Varmus stepped down as director of the National Cancer Institute in 2015, Douglas Lowy has filled in as acting director. Varmus, whose lab is based at Weill Cornell Medicine, echoes the praise, telling Science: “From everything I know, this is an excellent choice.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.